Suppr超能文献

服用高剂量吸入性二丙酸倍氯米松和间歇性全身用皮质类固醇的哮喘患者的骨密度

Bone density in asthmatic patients taking high dose inhaled beclomethasone dipropionate and intermittent systemic corticosteroids.

作者信息

Packe G E, Douglas J G, McDonald A F, Robins S P, Reid D M

机构信息

Department of Thoracic Medicine, Aberdeen Royal Infirmary.

出版信息

Thorax. 1992 Jun;47(6):414-7. doi: 10.1136/thx.47.6.414.

Abstract

BACKGROUND

Asthmatic patients taking low to moderate doses of inhaled topical corticosteroids have been shown to have lower bone density than those taking bronchodilators only. There is little information on bone density in asthmatic patients taking high dose inhaled corticosteroids.

METHODS

Bone mass was studied in three age matched groups of asthmatic patients. These comprised: 17 asthmatic patients who had never taken inhaled or systemic corticosteroids (group 1); 20 patients who had taken beclomethasone diproprionate in a dosage of 1000-2000 micrograms daily for at least a year, who had also received courses of systemic corticosteroids in the past (group 2); and 20 patients who were taking both high dose inhaled corticosteroids and regular low dose prednisolone, at a median dose of 7 mg daily (group 3). Vertebral bone density was measured by quantitative computed tomography. Biochemical indices of bone formation and resorption were also measured.

RESULTS

Mean bone density in group 2 (127.5(22.6) mg/ml) was similar to that in group 3 (114.5 (36.0) mg/ml). Bone density was significantly lower in both of these groups than in group 1 (160.4 (27.4) mg/ml). There were no significant differences between groups for any of the markers of bone formation and resorption.

CONCLUSIONS

Asthmatic patients receiving high dose inhaled beclomethasone and intermittent courses of systemic corticosteroids have reduced vertebral bone density. The bone loss is similar in degree to that seen in patients taking high dose inhaled topical corticosteroids and continuous low dose systemic corticosteroids.

摘要

背景

研究表明,服用低至中等剂量吸入性局部糖皮质激素的哮喘患者的骨密度低于仅服用支气管扩张剂的患者。关于服用高剂量吸入性糖皮质激素的哮喘患者的骨密度信息很少。

方法

对三组年龄匹配的哮喘患者进行骨量研究。这些组包括:17名从未服用过吸入性或全身性糖皮质激素的哮喘患者(第1组);20名每天服用1000 - 2000微克丙酸倍氯米松至少一年且过去也接受过全身性糖皮质激素疗程治疗的患者(第2组);以及20名同时服用高剂量吸入性糖皮质激素和常规低剂量泼尼松龙(中位剂量为每日7毫克)的患者(第3组)。通过定量计算机断层扫描测量椎体骨密度。还测量了骨形成和骨吸收的生化指标。

结果

第2组的平均骨密度(127.5(22.6)毫克/毫升)与第3组(114.5(36.0)毫克/毫升)相似。这两组的骨密度均显著低于第1组(160.4(27.4)毫克/毫升)。骨形成和骨吸收的任何标志物在各组之间均无显著差异。

结论

接受高剂量吸入性倍氯米松和间歇性全身性糖皮质激素疗程治疗的哮喘患者椎体骨密度降低。骨质流失的程度与服用高剂量吸入性局部糖皮质激素和持续低剂量全身性糖皮质激素的患者相似。

相似文献

6
Bone mineral density in asthmatic patients treated with inhaled corticosteroids: a case-control study.
Eur Respir J. 1997 Sep;10(9):2110-3. doi: 10.1183/09031936.97.10092110.

引用本文的文献

1
The risk of osteoporosis in patients with asthma.哮喘患者患骨质疏松症的风险。
Eur Clin Respir J. 2020 May 19;7(1):1763612. doi: 10.1080/20018525.2020.1763612. eCollection 2020.
7
8
Corticosteroid-sparing options in the treatment of childhood asthma.儿童哮喘治疗中减少皮质类固醇使用的选择
Drugs. 2000;59 Suppl 1:15-22; discussion 43-5. doi: 10.2165/00003495-200059001-00003.

本文引用的文献

1
Glucocorticoid-induced osteoporosis.糖皮质激素性骨质疏松症
N Engl J Med. 1983 Aug 4;309(5):306-8. doi: 10.1056/NEJM198308043090509.
3
High-dose beclomethasone inhaler in the treatment of asthma.高剂量倍氯米松吸入器治疗哮喘
Lancet. 1983 Feb 5;1(8319):265-9. doi: 10.1016/s0140-6736(83)91686-0.
8
Corticosteroids and bone mass in asthma.哮喘中的皮质类固醇与骨量
Br Med J (Clin Res Ed). 1987 Jan 10;294(6564):123. doi: 10.1136/bmj.294.6564.123-a.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验